Reid M. Huber

Partner at Third Rock Ventures LLC

Reid M. Huber

Reid M. Huber

Partner at Third Rock Ventures LLC

Overview
Career Highlights

MOMA Therapeutics, Inc.

RelSci Relationships

2180

Birthday

1972

Age

49

Contact Data
Trying to get in touch with Reid M. Huber? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Reid M. Huber likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Relay Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at MOMA Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

President & Chief Executive Officer, Director at Bellicum Pharmaceuticals Inc.

Relationship likelihood: Strong

Former Vice President & General Manager-Oncology Business Unit at Amgen, Inc.

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Former Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Paths to Reid M. Huber
Potential Connections via
Relationship Science
You
Reid M. Huber
Partner at Third Rock Ventures LLC
Education

A leader in medical research, teaching and patient care, Washington University School of Medicine is currently ranked fourth in the nation by U.S. News & World Report. The School's 2,100 employed and volunteer faculty physicians and clinicians -- known as Washington University Physicians -- are also medical staff members of Barnes-Jewish and St. Louis Children's hospitals. The clinical practice group provides care to more than 430,000 children and adults at 49 clinical sites annually. Together, the institutions located on the Washington University Medical Center campus employ more than 21,000 clinicians, scientists, residents, fellows, administrators and support staff.

Career History
Chief Scientific Officer & Executive Vice President
2002 - 2018

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Principal Research Scientist
1998 - 2002

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

Partner
2018 - Current

Third Rock Ventures invests in companies located in the US. The firm targets operating in the fields of healthcare sector. It provides financing for early-stage capital requirements. It also acts as a lead investor.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Reid M. Huber. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Reid M. Huber's profile does not indicate a business or promotional relationship of any kind between RelSci and Reid M. Huber.